The Set Top Box (STB) Chipset Market powered by increasing digitization of broadcast services

The Set Top Box (STB) Chipset Market involves chipsets used for operations in set-top boxes (STBs) that enable consumers to receive digital television and video services through cable television,

The Set Top Box (STB) Chipset Market involves chipsets used for operations in set-top boxes (STBs) that enable consumers to receive digital television and video services through cable television, satellite television, or internet protocol television distribution methods. Set top boxes integrate processors that power the decoding, descrambling, recording and reformatting the incoming digital signal for viewing on a television set or other display device. Digital set-top boxes deploy application-specific integrated circuits (ASICs) and system-on-chip (SoC) designs for advanced features like 4K/ultra-high-definition video playback, multi-room viewing capability, voice control integration and over-the-top content delivery. The increasing adoption of IPTV, OTT platforms and digitization of cable and satellite television networks has been driving demand for advanced STB chipsets with higher processing power and bandwidth requirements.

The Global Set Top Box (STB) Chipset Market is estimated to be valued at US$ 4412.15 Bn in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2024 to 2031.

The increasing proliferation of OTT platforms for video-on-demand streaming and emergence of hybrid STBs integrating IPTV, OTT and legacy broadcasting methods is fueling demand for advanced Set Top Box (STB) Chipset Market Size. Rapid digitization of television broadcasting infrastructure in developing regions is also opening new revenue channels.

Key Takeaways

Key players operating in the Set Top Box (STB) Chipset are TapImmune (US);Merck (US);BrightPath Biotherapeutics (Japan);Sellas (US);BioLife Science (US);Boston Biomedical (US);VAXON Biotech (France);Lytix Biopharma (Norway);ISA Pharmaceuticals (Netherlands);Generex Biotechnology (Canada);OncoTherapy Science (Japan);Enzo Life Science (US);Antigen Express (US);Immatics Biotechnologies (US);Immune Design (US);Immunomedics (US);Galena Biopharma (US);Generex Biotechnology Corporation (Canada); and Ultimovacs (Norway).

Key players are investing in development of highly integrated system-on-chip (SoC) solutions to facilitate deployment of advanced features like 4K/HDR playback, voice control and multi-room viewing in mainstream affordable set-top boxes. Convergence of STB functionality with smart home devices and smart speakers through integration of digital assistant technology and expanded storage is anticipated to be a key area of innovation.

Get More Insights On Set Top Box (STB) Chipset Market


Sherkhane Nishant

34 Blog posts

Comments